| HOME >> BIOLOGY >> TECHNOLOGY |
Cardium's Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this
press release are forward looking and reflect numerous assumptions and
involve a variety of risks and uncertainties, many of which are beyond our
control and may cause actual results to differ materially from stated
expectations. For example, there can be no assurance that results or trends
observed in one clinical study or procedure will be reproduced in
subsequent studies or procedures, that human clinical trials can be
conducted and completed in an efficient and successful manner, that FDA, CE
Mark or other regulatory clearances or UL or other certifications, or
partnering or other distribution agreements or other commercialization
efforts will be successful or will effectively accelerate the business or
market, that product modifications or launches will be successful or that
the resulting products will be favorably received in the marketplace, that
our products or product candidates will prove to be sufficiently safe and
effective, that necessary regulatory approvals will be obtaine
'/>"/>
| SOURCE Cardium Therapeutics Copyright©2008 PR Newswire. All rights reserved |